News
Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Viking is developing what might be a game-changing medication in the segment.
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...
Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.
The World Health Organization plans to endorse weight-loss drugs for treating obesity in adults, marking a strategic change.
1d
Investor's Business Daily on MSNEli Lilly Bounces Back. Zepbound Taking A Back Seat To Novo Nordisk's Wegovy At CVS.Eli Lilly rose Friday after topping Wall Street's first-quarter expectations. Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred ...
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...
Losing even a moderate amount of weight is associated with reduced progression of diabetes, improved blood pressure and HDL ...
In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results